DXO-1801 / Dexoligo Therapeutics, Dexcel Pharma - LARVOL DELTA

DXO-1801, A HEPATOCYTE-TARGETED GALNAC-SIRNA, DEMONSTRATES HEPCIDIN PATHWAY MODULATION, IRON MOBILIZATION, AND A FAVORABLE SAFETY PROFILE IN NON-HUMAN PRIMATES (EHA 2026) - "DXO-1801 was well tolerated across a wide dose range, providing a >100-fold dose margin between the pharmacologically active dose and the highest evaluated, well-tolerated dose (300 mg/kg). These findings support the potential for infrequent dosing, predictable exposure–response relationship and favorable therapeutic index in future clinical studies."

Clinical • Hematological Disorders • Hepatology • Liver Failure